GEN Exclusives

More »

GEN News Highlights

More »
May 8, 2014

CRISPR Technique Added to Horizon’s Gene Editing Platform Portfolio

  • Horizon Discovery signed a nonexclusive license agreement with ERS Genomics to access intellectual property relating to the CRISPR/Cas9 gene editing system. Horizon has rights to use the technology for research applications including development and sale of research tools, kits, and reagents, performance of research services, creation of genetically modified disease model cell lines, development and production of reference standard material for molecular diagnostics, and for internal target identification and validation research efforts.

    "The acquisition of this CRISPR IP is in line with the company’s aims outlined at the time of its IPO and further strengthens Horizon’s long-term position in the market for this cutting-edge gene editing technology," explained Darrin Disley, Ph.D., CEO of Horizon Discovery. "Access to a broader CRISPR IP portfolio will allow the technology to be deployed extensively across Horizon’s products, services, and leveraged R&D and further enhance the attractiveness of the company’s core genome-editing platform Genesis™ to customers," he added.

    For more on CRISPR, be sure to check out our BioPerspective "CRISPR Gene Editing: It Isn't Quite As Easy As It Looks".


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Children and Antipsychotic Drugs

Do you think children and adolescents with behavioral problems are overmedicated?